 |
bivalirudin |
|---|---|
| Trade Name | Angiomax |
| Orphan Indication | For use as an anticoagulant in patients with or at risk of heparin-induced thrombocytopenia/heparin-induced thrombocytopenia thrombosis syndrome |
| USA Market Approval | USA |
| USA Designation Date | 2005-11-02 00:00:00 |
| Sponsor | The Medicines Company;8 Sylvan Way;Parsippany, New Jersey, 07054 |
